General Counsel Sandra Leung discusses the legal ramifications of Bristol-Myers Squibb's transformation into a "next-generation biopharmaceutical company."
General Counsel Profile: Bristol-Myers Squibb Co.
The National Law Journal
October 12, 2010
This article requires premium access
This article requires free registration to The National Law Journal. Please sign in or register to read the full text.